Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
Daniel J. Rader, … , Jonathan Cohen, Helen H. Hobbs
Daniel J. Rader, … , Jonathan Cohen, Helen H. Hobbs
Published June 15, 2003
Citation Information: J Clin Invest. 2003;111(12):1795-1803. https://doi.org/10.1172/JCI18925.
View: Text | PDF
Science in Medicine

Monogenic hypercholesterolemia: new insights in pathogenesis and treatment

  • Text
  • PDF
Abstract

Authors

Daniel J. Rader, Jonathan Cohen, Helen H. Hobbs

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Overview of LDL metabolism in humans. Dietary cholesterol and triglyceri...
Overview of LDL metabolism in humans. Dietary cholesterol and triglycerides are packaged with apolipoproteins in the enterocytes of the small intestine, secreted into the lymphatic system as chylomicrons (CM). As chylomicrons circulate, the core triglycerides are hydrolyzed by lipoprotein lipase, resulting in the formation of chylomicron remnants (CM Rem), which are rapidly removed by the liver. Dietary cholesterol has four possible fates once it reaches the liver: it can be esterified and stored as cholesteryl esters in hepatocytes; packaged into VLDL particles and secreted into the plasma; secreted directly into the bile; or converted into bile acids and secreted into the bile. VLDL particles secreted into the plasma undergo lipolysis to form VLDL remnants (VLDL Rem). Approximately 50% of VLDL remnants are removed by the liver via the LDLR, and the remainder mature into LDL, the major cholesterol transport particle in the blood. An estimated 70% of circulating LDL is cleared by LDLR in the liver. ABCG5 and ABCG8 are located predominantly in the enterocytes of the duodenum and jejunum, the sites of uptake of dietary sterols, and in hepatocytes, where they participate in sterol trafficking into bile. Mutations in either transporter cause an increase in delivery of dietary sterols to the liver and a decrease in secretion of sterols into the bile. Autosomal recessive hypercholesterolemia (ARH) is a putative adaptor protein that is involved in the mechanics of LDLR-mediated endocytosis. ABCG: ATP-binding cassette, family G.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts